Circulation, Vol 83, 1256-1262, Copyright © 1991 by American Heart Association
F Lattanzi, E Picano, L Bolognese, C Piccinino, G Sarasso, A Orlandini and A L'Abbate
BACKGROUND. Dipyridamole echocardiography test (DET: two-dimensional
echocardiographic monitoring with dipyridamole infusion up to 0.84 mg/kg in
10 minutes) is a useful tool for the noninvasive diagnosis of coronary
artery disease. Aims of the present study were to assess the effects of
antianginal drugs on dipyridamole-induced ischemia and to evaluate whether
drug-induced changes in DET response may predict variations in exercise
tolerance. METHODS AND RESULTS. Fifty-seven patients with angiographically
assessed significant coronary artery disease (greater than 70% lumen
reduction in at least one major coronary vessel) performed a DET and an
exercise electrocardiography test (EET) in random order both off treatment
and on antianginal drugs (beta-blockers, calcium antagonists and nitrates,
alone or in various combinations). The criterion for DET positivity was a
transient dyssynergy of contraction absent or of a lesser degree in the
baseline examination. In DET, two parameters were evaluated: the
dipyridamole time (i.e., the time from onset of dipyridamole infusion to
obvious dyssynergy) and the wall motion score index. DET sensitivity was
91% off therapy and fell to 65% under therapy (p less than 0.01). In the 37
patients who had a positive DET both off and on therapy, the dipyridamole
time increased from 6 +/- 3 (off therapy) to 8 +/- 3 minutes (on therapy)
(p less than 0.01). The wall motion score index at peak dipyridamole went
from 1.38 +/- 0.14 to 1.31 +/- 0.14 (p less than 0.01). EET and DET yielded
concordant (positive versus negative) results in 41 of 57 (71%) patients
off and in 35 of 57 (61%) on therapy (p = NS). In the subgroup of 38
patients with both positive DET and EET without treatment, the
therapy-induced variations in exercise time were significantly correlated
with the variations in dipyridamole time (r = 0.5; p less than 0.01), not
with variations in wall motion score index (r = 0.3; p = NS). CONCLUSIONS.
1) Antianginal therapy can protect from dipyridamole-induced ischemia and
2) the therapy-induced changes in DET response parallel variations in
exercise tolerance and might be useful for the objective,
exercise-independent assessment of the therapy efficacy.
ARTICLES
Inhibition of dipyridamole-induced ischemia by antianginal therapy in humans. Correlation with exercise electrocardiography
C.N.R. Clinical Physiology Institute, University of Pisa, Italy.
This article has been cited by other articles:
 |
|
 |
|
  F. Rigo, R. Sicari, S. Gherardi, A. Djordjevic-Dikic, L. Cortigiani, and E. Picano The additive prognostic value of wall motion abnormalities and coronary flow reserve during dipyridamole stress echo Eur. Heart J., January 1, 2008; 29(1): 79 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cortigiani, F. Rigo, S. Gherardi, R. Sicari, M. Galderisi, F. Bovenzi, and E. Picano Additional Prognostic Value of Coronary Flow Reserve in Diabetic and Nondiabetic Patients With Negative Dipyridamole Stress Echocardiography by Wall Motion Criteria J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sicari, L. Cortigiani, R. Bigi, P. Landi, M. Raciti, E. Picano, and for the Echo-Persantine International Cooperative Prognostic Value of Pharmacological Stress Echocardiography Is Affected by Concomitant Antiischemic Therapy at the Time of Testing Circulation, May 25, 2004; 109(20): 2428 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Taillefer, A. W. Ahlberg, Y. Masood, C. M. White, I. Lamargese, J. F. Mather, C. C. McGill, and G. V. Heller Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1475 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Gerson Reduction in dipyridamole-induced single-photon emission computed tomography myocardial defect size by beta-blockers: Time to re-examine the patient preparation protocol for pharmacologic stress testing J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1484 - 1486. [Full Text] [PDF]
|
|
|
|
|
|
A. Desideri, P. M. Fioretti, L. Cortigiani, D. Gregori, C. Coletta, C. Vigna, F. Tota, R. Rambaldi, J. Bax, L. Celegon, et al. Cost of strategies after myocardial infarction (COSTAMI): A multicentre, international, randomized trial for cost-effective discharge after uncomplicated myocardial infarction Eur. Heart J., September 2, 2003; 24(18): 1630 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Poggianti, L. Venneri, V. Chubuchny, Z. Jambrik, L. A. Baroncini, and E. Picano Aortic valve sclerosis is associatedwith systemic endothelial dysfunction J. Am. Coll. Cardiol., January 1, 2003; 41(1): 136 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Palinkas, E. Toth, R. Amyot, F. Rigo, L. Venneri, and E. Picano The value of ECG and echocardiography during stress testing for identifying systemic endothelial dysfunction and epicardial artery stenosis Eur. Heart J., October 2, 2002; 23(20): 1587 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Picano and C. Michelassi Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis Cardiovasc Res, March 1, 1997; 33(3): 666 - 670. [Abstract] [PDF]
|
|